AU2011284341A1

AU2011284341A1 - N-Methylformamide solvate of dasatinib

Info

Publication number: AU2011284341A1
Application number: AU2011284341A
Authority: AU
Inventors: Sudershan Kumar Arora; Jagdev Singh Jaryal; Saridi Madhava Dileep Kumar; Mohan Prasad; Sudhir Singh Sanwal; Swargam Sathyanarayana; Rajesh Kumar Thaper
Original assignee: Ranbaxy Laboratories Ltd
Current assignee: Ranbaxy Laboratories Ltd
Priority date: 2010-07-30
Filing date: 2011-07-25
Publication date: 2013-02-21
Also published as: WO2012014149A1; EP2598147A1; CA2806820A1

Abstract

The present invention relates to the N-Methylformamide solvate of dasatinib a process for its preparation. Formula (I)

Description

WO 2012/014149 PCT/IB2011/053318 N-METHYLFORMAMIDE SOLVATE OF DASATINIB Field of the Invention The present invention relates to a N-Methylformamide solvate of dasatinib and a process for its preparation. 5 Background of the Invention Dasatinib monohydrate of Formula A, chemically described as N-(2-chloro-6 methylphenyl)-2-[[6-[4-(2-hydroxyethyl)- 1 -piperazinyl]-2-methyl-4-pyrimidinyl]amino] 5-thiazole carboxamide monohydrate, is a cyclic protein tyrosine kinase inhibitor. Dasatinib monohydrate, marketed under the brand name Sprycel@, is indicated for the 10 treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib. Sprycel@ is also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.

CH

3

CH

3 ON N NH NH N H 2 0 -- N 15 C1 N OH Formula A U.S. Patent No. 6,596,746 provides a process for the preparation of dasatinib. U.S. Patent No. 7,491,725 provides for the crystalline monohydrate, butanol solvate forn, crystalline ethanol solvates and neat forms of dasatinib. It also provides a 20 process for the preparation of crystalline monohydrate, butanol solvate form, crystalline ethanol solvate and neat form of dasatinib. U.S. Publication No. 2009/0118297 provides for the anhydrous form, amorphous form, iso-propanol solvate, a n-propanol-dimethylsulfoxide ("DMSO") solvate, a DMSO solvate, a hemi tetrahydrofuran ("THF") solvate, a 2-methyl-tetrahydrofuran ("2-methyl 25 THF") solvate, a hemi 1,4-dioxane solvate, a pyridine solvate, a toluene solvate, a methyl WO 2012/014149 PCT/IB2011/053318 2 isobutyl ketone ("MIBK") solvate, a mono acetone solvate, an iso-propanol ("IPA") DMSO solvate, a 2-butanol-DMSO solvate, an IPA-DMF solvate, an IPA solvate, an n propanol-DMF solvate, an n-propanol solvate, a 2-butanol-DMF solvate, a 2-butanol solvate, an n-butanol-DMSO solvate, a DMF-water solvate, a DMF solvate, a methyl 5 isopropyl ketone ("MIPK") solvate, a dimethoxyethane solvate, a cellosolve solvate, a methylacetate solvate, a methanol solvate, an ethylacetate solvate, a 2-pentanole solvate, a dimethyl carbonate solvate, an isopropylacetate solvate, an ethyleneglycol solvate, a dichloromethane solvate, a methylformate solvate, a tert-butanol solvate, a dimethoxyethane solvate, a methylethylketone ("MEK") solvate, a monochlorobenzene 10 solvate, a propylene glycol monoethyl ether ("PGME") solvate, a glycerol solvate, a cyclopentyl methyl ether solvate, a methyl tert butyl ether ("MTBE") solvate, an amylalcohol solvate, a glycerol formal solvate of dasatinib and processes for their preparation. WO 2010/062715 discloses an isosorbide dimethyl ether solvate of dasatinib, a 15 N,N'-dimethylethylene urea solvate of dasatinib, and a N,N'-dimethyl-N,N'-propylene urea solvate of dasatinib and processes for their preparation. WO 2010/067374 discloses a dimethylformamide solvate, dimethyl sulfoxide solvate, toluene solvate, isopropyl acetate solvate, crystalline Form I of dasatinib characterized by their X-ray powder diffractogram and processes for their preparation. 20 Polymorphism is defined as the ability of a substance to exist as two or more crystalline phases that have different arrangements and/or conformations of the molecule in the crystal lattice. Different polymorphs may differ in their physical properties, such as, melting point, solubility, X-ray diffraction patterns, and the like. Although these differences disappear once the compound is dissolved, they can appreciably influence the 25 pharmaceutically relevant properties of the solid form, such as its handling properties, dissolution rate and stability. Such properties can significantly influence the processing, the shelf life, and the commercial acceptance of a polymorph. Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray Diffraction (XRD) powder as well as single crystal, DSC, IR, Solid state NMR, or Raman 30 spectroscopy.

WO 2012/014149 PCT/IB2011/053318 3 The solvent medium and/or mode of isolation play a very important role in obtaining one polymorphic form over another. The discovery of new solid state forms and solvates of a pharmaceutical compound provides a new opportunity to improve the pharmacokinetic properties of a pharmaceutical 5 product. Therefore, there is a need for additional solid state forms of dasatinib. The present inventors have now surprisingly found a N-Methylformamide solvate of dasatinib. The novel N-Methylformamide solvate of dasatinib of the present invention is suitable for preparing pharmaceutical compositions. Summary of the Invention 10 In one general aspect, the present invention provides for N-Methylformamide solvate of dasatinib of Formula B. 0

CH

3 1 CH 3 CH3 O H NH I N NH NH N NN CI N OH Formula B In another general aspect, the present invention provides for crystalline N 15 Methylformamide solvate of dasatinib characterized by an X-Ray Powder Diffractogram (XRPD) substantially as depicted in Figure 1. In another general aspect, the present invention provides for crystalline N Methylformamide solvate of dasatinib characterized by an X-ray Powder Diffractogram which includes interplanar distances at approximately 14.21, 7.11, 5.80, 4.74, and 3.65 A. 20 Embodiments of this aspect may include one or more of the following features. For example, the crystalline N-Methylformamide solvate of dasatinib may be further characterized by an X-ray Powder Diffractogram which includes interplanar distance at approximately 7.45, 4.83, 4.29, 3.82, 3.73 and 3.49 A. The crystalline N-Methylformamide solvate of dasatinib may further be 25 characterized by a DSC thermogram substantially as depicted in Figure 2. For example, WO 2012/014149 PCT/IB2011/053318 4 the crystalline N-Methylformamide solvate of dasatinib may have characteristic DSC endothermic peaks at about 160'C and about 287 0 C. The crystalline N-Methylformamide solvate of dasatinib may also be further characterized by a TGA substantially as depicted in Figure 3. 5 In yet another general aspect, the present invention provides for a process for the preparation of N-Methylformamide solvate of dasatinib. The process includes: a) treating dasatinib with N-Methylformamide; and b) isolating N-Methylformamide solvate of dasatinib. Embodiments of this aspect may include one or more of the following features. 10 For example, step a) is carried out at a temperature of 20*C to 50'C and the amount of N Methylformamide is 3 to 10 times the amount of dasatinib. In another general aspect, the present invention provides for the use of N Methylformamide solvate of dasatinib for the preparation of other polymorphic forms or solvates of dasatinib. 15 In yet another general aspect, the present invention provides for a pharmaceutical composition which includes a therapeutically effective amount of N-Methylformamide solvate of dasatinib and one or more pharmaceutically acceptable excipients. In another general aspect, the present invention provides for a method for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic 20 myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. The method includes administering to a mammal in need thereof a therapeutically effective amount of N-Methylformamide solvate of dasatinib. 25 Brief Description of the Drawings Figure 1 and Figure la depicts X-Ray Powder Diffractogram (XRPD) of N Methylformamide solvate of dasatinib and the associated values, respectively. Figure 2 depicts Differential Scanning Calorimetry (DSC) thermogram of N Methylformamide solvate of dasatinib.

WO 2012/014149 PCT/IB2011/053318 5 Figure 3 depicts Thermogravimetric Analysis (TGA) of N-Methylformamide solvate of dasatinib. The XRPD was determined by using PANalytical X' Pert Pro X-Ray Powder Diffractometer in the range 0 0 C to 40'C 20 and under tube voltage and current of 45 Kv 5 and 40 mA, respectively. Copper radiation of wavelength 1.54 angstrom and Xceletor detector was used. The TGA was recorded on TA (Q500) (Rate of heating = 10 C/minute). The DSC was recorded on Mettler Toledo (DSC 821) (Rate of heating = 1 0 0 C/minute). 10 Detailed Description of the Invention The present invention provides for the N-Methylformamide solvate of dasatinib of Formula B 0

CH

3 -CH 3 CH3 O H NH NH C SNN CI N N " OH Formula B 15 The present invention may be in the form of crystalline N-Methylformamide solvate of dasatinib. The crystalline N-Methylformamide solvate of dasatinib has an X-Ray Powder Diffractogram (XRPD) substantially as depicted in Figure 1 of the accompanied drawings. The crystalline N-Methylformamide solvate of dasatinib has an X-ray 20 Powder Diffractogram which shows characteristic peaks expressed as interplanar distance at approximately 14.21, 7.11, 5.80, 4.74, and 3.65 A. The crystalline N Methylformamide solvate of dasatinib may be further characterized by peaks expressed as interplanar distance at approximately 7.45, 4.83, 4.29, 3.82, 3.73 and 3.49

A.

WO 2012/014149 PCT/IB2011/053318 6 The crystalline N-Methylformamide solvate of dasatinib has a DSC thermogram substantially as depicted in Figure 2 of the accompanied drawings. The DSC thermogram shows characteristic endothermic peaks at about 160'C and about 287 0 C. 5 The crystalline N-Methylformamide solvate of dasatinib has a TGA substantially as depicted in Figure 3 of the accompanied drawings. The TGA of the crystalline N-Methylformamide solvate of dasatinib shows a weight loss of about 10.6%. The present invention also provides for a process for the preparation of N 10 Methylformamide solvate of dasatinib. The process includes: a) treating dasatinib with N-Methylformamide; and b) isolating N-Methylformamide solvate of dasatinib. Dasatinib in any previously known crystalline or amorphous form prepared by methods known in the art can be used as the starting material. 15 Step a) of the process involves adding dasatinib to N-Methylformamide or adding N-Methylformamide to dasatinib in optional order of succession at a suitable temperature of between 20'C to 50'C; preferably under stirring. For example, the addition may be performed at a temperature of between 20'C to 35'C. N-Methylformamide may be used in an amount of 3 to 10 times the amount of 20 dasatinib. After the completion of addition, the resultant mixture is heated to a temperature of between about 50'C to 80'C for about 15 minutes to 3 hours. For example, it may be heated at about 60'C to 70'C. Step b) of the process involves isolating N-Methylformamide solvate of dasatinib 25 through common isolation techniques, such as one or more of washing, crystallization, precipitation, cooling, filtration, filtration under vacuum, decantation and centrifugation, or a combination thereof. For example, step b) involves filtration of the reaction mass obtained in step a) to remove foreign particulate matter or treated with activated charcoal to remove coloring WO 2012/014149 PCT/IB2011/053318 7 and other related impurities. The filtrate is maintained at about 10 C to 40'C for a time period of 2 hours to 24 hours to allow the N-Methylformamide solvate of dasatinib to crystallize. The isolated crystalline N-Methylformamide solvate of dasatinib may be dried at 5 40'C to 60'C under vacuum for about 12 hours to 28 hours. The N-Methylformamide solvate of dasatinib may also be used for the preparation of other polymorphic forms or solvates of dasatinib. The present invention also provides for a pharmaceutical composition that includes a therapeutically effective amount of N-Methylformamide solvate of dasatinib and one or 10 more pharmaceutically acceptable excipient. The present invention also provides for a method for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia 15 (Ph+ ALL) with resistance or intolerance to prior therapy. The method includes administering to a mammal in need thereof a therapeutically effective amount of N Methylformamide solvate of dasatinib. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the 20 art and are intended to be included within the scope of the present invention. EXAMPLE Preparation of N-Methylformamide Solvate of Dasatinib Dasatinib (3.24 g) was charged in a round bottom flask. N-methyl formamide (20 ml) was added to it. The reaction mixture was heated at 70*C for 30 minutes and filtered. 25 The filtrate was collected in a beaker and kept at a temperature of 20'C to 35'C overnight for crystallization. The solid was filtered and suck dried for 30 minutes. Solid was unloaded and dried under a vacuum at 55 0 C to 60'C for 24 hours to obtain the title compound. Yield: 1.95 g

Claims

Claims: 1. N-Methylformarnide solvate of dasatinib of Formula B.

Formula B
2. Crystalline N-Methylformamide solvate of dasatinib characterized by an X-Ray Powder Diffractogram (XRPD) substantially as depicted in Figure 1.
3. Crystalline N-Methylformamide solvate of dasatinib characterized by an X-ray Powder Diffractogram comprising interplanar distance at approximately 14.21, 7.1 1 , 5.80, 4.74, and 3.65 A.
4. The crystalline N-Methylformamide solvate of dasatinib according to claim 3, further characterized by an X-ray Powder Diffractogram comprising interplanar distance at approximately 7.45, 4.83, 4.29, 3.82, 3.73 and 3.49 A.
5. The crystalline N-Methylformamide solvate of dasatinib according to claim 2, further characterized by a DSC thermogram substantially as depicted in Figure 2.
6. The crystalline N-Methylformamide solvate of dasatinib according to claim 2, further comprising a DSC having characteristic endothermic peaks at about 160°C and about 287°C.
7. The crystalline N-Methylformamide solvate of dasatinib according to claim 2, further characterized by a TGA substantially as depicted in Figure 3.
8. A process for the preparation of N-Methylformarnide solvate of dasatinib, the process comprising: c) treating dasatinib with N-Methylformarnide; and d) isolating N-Methylformamide solvate of dasatinib.
9. A process according to claim 8, wherein step a) is carried out at a temperature of 20°C to 50°C.
10. A process according to claim 8, wherein the amount of N-Methylformamide is 3 to 10 times the amount of dasatinib.
1 1. Use of N-Methylformamide solvate of dasatinib for the preparation of other polymorphic forms or solvates of dasatinib.
12. A pharmaceutical composition comprising a therapeutically effective amount of N- Methylformamide solvate of dasatinib and one or more pharmaceutically acceptable excipients.
13. A method for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy, the method comprising administering to a mammal in need thereof a therapeutically effective amount of N-Methylformamide solvate of dasatinib.